CBD /mL
Phase 3Small molecule
CBD /mL is one of 39 small molecule programs targeting Psychosis. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Psychosis
#DrugCompanyPhaseTrials
1Geodon
PfizerApproved
Abilify
OtsukaApproved
Cysteine Hydrochloride
NovartisApproved
Risperdal
WWim Janssens
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Niacor
AbbVieApproved
Zyprexa
MMODAG GmbH
Approved
Vraylar
AbbVieApproved
Barhemsys
Tibotec Pharmaceuticals, IrelandApproved
Invega
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBD /mL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Oxford